ADMA Biologics, Inc.
NASDAQ:ADMA · NASDAQ Global Market
+$0.04 today
Vol 6.84M · Avg 7.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.8%
avg -226.3%
ROIC
27.6%
avg -29.9%
ROA
23.5%
avg -30.6%
Analysis
ROE is currently the strongest return metric at 30.8% versus its period average of -226.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Adam S. Grossman | Co-Founder, President, Chief Executive Officer & Director | $2.14M | — | 49 | $520,284.00 | 0.22% |
Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | $988,659.00 | — | 39 | $446,238.00 | 0.19% |
Brad Tade | Consultant | $823,645.00 | — | 52 | $232,940.00 | 0.10% |
Jerrold Grossman | Co-Founder & Vice Chairman of the Board | $90,000.00 | — | 78 | $520,284.00 | 0.22% |
Terence Kohler | Chief Financial Officer & Treasurer | $46,973.00 | — | — | $0.00 | <0.01% |
Skyler Bloom | Senior Director of Business Development & Corporate Strategy | — | — | — | — | — |
Michael Goldstein | General Counsel | — | — | — | $7,500.00 | <0.01% |
John Hafl | Executive Director of Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$468,294.00
Sells
17
$2.99M
Net Sentiment
$2.52M
Net selling
Most Active
Grossman Adam S
16 transactions
1–10 of 22
Analysis
Insiders reported 5 buys worth $468,294.00 and 17 sells worth $2.99M over the last 12 months. That adds up to net selling of $2.52M. Grossman Adam S was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +85.9% | +38.5% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +85.9% over three years. Forward estimates point to Revenue at +38.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.84B
Belite Bio, Inc
NASDAQ:BLTE
$5.78B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.35B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.27B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.74B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.65B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.40B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.22B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Who manages ADMA?
ADMA Biologics, Inc. (ADMA) lists 8 active executives. The top listed executive is Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President of Compliance.
Are ADMA insiders buying or selling?
Recent insider activity shows net selling of $9.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.